Tracks kidney and blood pressure health in childhood cancer survivors
Follows childhood cancer survivors to see if kidney disease or high blood pressure develops.
Plain-language title generated from the registry record
Registry title: KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for childhood cancer survivors who finished treatment for their first cancer about 3 years ago and had high-risk therapy that may harm the kidneys or blood pressure.
- Age
- Up to 19 years old at 3 years after cancer therapy ended.
- Sex
- All sexes can join.
- Disease stage
- Survivors of a first childhood cancer who received high-risk therapy.
- Earlier treatment
- Must have had high-risk therapy for the first cancer: alkylating agents, platinums, abdominal or total body radiation, high dose methotrexate, stem cell transplant, nephrectomy, or other therapy that may cause late kidney or blood pressure effects.
Main reasons for not taking part
- Severe chronic kidney disease before the cancer
- Previous kidney transplant
- Older than 19 years at 3 years after cancer therapy ended
Read by machine on 12 November 2026.
Where in Canada
- The Hospital for Sick ChildrenToronto, CanadaContact: Yasmine Hejri-Rad, BATaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Hospital for Sick Children
- Trial code
- NCT06153147
- Record updated
- 17 April 2024
- Original description
Background: Childhood cancer survivors (CCS) are at elevated risk of chronic health conditions. Chemotherapies can cause recurrent acute kidney injury which may progress to kidney fibrosis, chronic kidney disease (CKD) or hypertension (HTN). CCS surviving to adulthood are at ≥3 times the risk (vs. non-CCS) for CKD, HTN and lower quality of life. However, the timing of CKD and HTN onset in CCS completing cancer therapy in childhood remains unclear.Read full original descriptionShow less
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS): Prospective Study
Background: Childhood cancer survivors (CCS) are at elevated risk of chronic health conditions. Chemotherapies can cause recurrent acute kidney injury which may progress to kidney fibrosis, chronic kidney disease (CKD) or hypertension (HTN). CCS surviving to adulthood are at ≥3 times the risk (vs. non-CCS) for CKD, HTN and lower quality of life. However, the timing of CKD and HTN onset in CCS completing cancer therapy in childhood remains unclear.
Guidelines provide recommendations on managing post-cancer therapy effects in CCS, but they lack specificity on kidney testing content, frequency and complications. This discord is largely due to knowledge gaps on which CCS develop CKD or HTN after cancer therapy, when outcomes occur and their severity. Existing work has shown in select patients, CKD and HTN in CCS likely begins in the first 5 years post-cancer therapy and that the burden is significant. With robust data on CKD and HTN, international CCS follow-up guidelines can be optimized to include detailed and actionable recommendations on kidney and blood pressure monitoring and treatment.
Inclusion: 3 years ± 6 months after therapy for first cancer; Received high-risk therapy for first cancer, as defined by the Canadian Oncology Group (COG) as alkylating agents; platinums; abdominal or total body radiation; high dose methotrexate; stem cell transplant; nephrectomy; or other therapy which may be known to possibly cause late kidney and/or BP effects.
Exclusion: Pre-cancer severe CKD and/or previous kidney transplant; >19 years old at 3 years after cancer therapy completion.